Ignyta (Ignyta) Margin of Safety % (DCF Earnings Based) : N/A (As of May. 06, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ignyta Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ignyta's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Ignyta's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Ignyta's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ignyta's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ignyta's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Ignyta's Margin of Safety % (DCF Earnings Based) falls into.

Ignyta Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Ignyta's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Ignyta (Ignyta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ignyta Inc (NAS:RXDX) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ignyta.com

Ignyta is an oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. The integrated therapeutic segment aims to discover, develop, and commercialize molecularly targeted therapies. The companion diagnostic segment aims to pair the discovered therapies with biomarker-based companion diagnostics to precisely identify, at the molecular level, patients likely to have good results. The company's portfolio includes compounds to treat adult patient populations for solid tumors, pediatric patients with advanced solid tumor malignancies, and patients with superficial and nodular basal cell carcinoma.

Executives

James L Freddo	director	3115 MERRYFIELD ROW, SAN DIEGO CA 92121
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Pratik S Multani	officer: Chief Medical Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Jonathan E Lim	director, 10 percent owner, officer: President, CEO & Director	11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jacob Chacko	officer: Chief Financial Officer	C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Igor Bilinsky	officer: GM, Immuno-Oncology/SVP Sp Ops	C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Matthew Onaitis	officer: General Counsel and Secretary	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Adrian Senderowicz	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024

Ignyta (Ignyta) Headlines

From GuruFocus

Steven Cohen Dives Deeper Into Health Care

By Graham Griffin Graham Griffin • 03-23-2021